All Clinical Trials
Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.
335 trials found
Drug [asc] |
NCT# |
||
|---|---|---|---|
| Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors | 4 |
||
| Symptom Inventory for Gastrointestinal Stromal Tumors | |||
| AMG 479 + AMG 655 | AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | 2 |
|
| AMG 706 | Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) | 2 |
|
| AMG 706 | Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors (Japan) | 2 |
|
| AMG 706 | An Open Label Treatment Extension Study of AMG 706 | 2 |
|
| Anlotinib | Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial | 2 |
|
| Apatinib Mesylate | Apatinib Mesylate (Rivoceranib) Versus Standard Second-line TKI in the Treatment of Advanced GIST | ||
| ARQ 092 | Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | 1 |
|
| AT13387 | Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors | 1 |
|
| AUY922 | Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor | 2 |
|
| AUY922 | A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients | 2 |
|
| AUY922 | Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients. | 1 |
|
| Avapritinib | Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST | ||
| Avapritinib | Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA | ||
| Avapritinib (CS3007) | A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor | 1/2 |
|
| Avapritinib or Regorafenib | (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST | 3 |
|
| Avelumab + Axitinib | C | 2 |
|
| Axitinib + Pembrolizumab | Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas | 2 |
|
| AZD2171 | Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours | 2 |
|
| AZD2171 (cediranib) | The Biological Activity of AZD2171 in GIST | 2 |
|
| AZD6244 plus Temsirolimus | MEK Inhibitor AZD6244 With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery | 2 |
|
| BAY80-6946 + BAY86-9766 | Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer | 1 |
|
| BBI503 | A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors | 1 |
|
| Belzutifan | Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) | 2 |
|
| Berzosertib | M6620 (VX-970) in Selected Solid Tumors | 2 |
|
| BEZ235 | A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer | 1 |
|
| BEZ235 + MEK162 | Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients | 1 |
|
| Bezuclastinib plus Sunitinib | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | 3 |
|
| Bezuclastinib plus Sunitinib | SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST | 2 |
|
| BGT226 | A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer | 1 |
|
| BIIB021 (CNF2024) | An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment | 2 |
|
| BIIB021 (CNF2024) | Study of Oral CNF2024 in Advanced Solid Tumors | 1 |
|
| BIIB021 (CNF2024) | Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors | 1 |
|
| BIIB022 | Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors | 1 |
|
| BIIB028 | Administration of BIIB028 to Subjects With Solid Tumors | 1 |
|
| Binimetinib + Pexidartinib | A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) | 1 |
|
| BKM120 | A Phase IA, Multi-Center, Open-Label, Dose- Escalation Study of BKM120, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients with Advanced Solid Malignancies | 1 |
|
| BKM120 + GSK1120212 | A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients | 1 |
|
| BKM120 + MEK162 | Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients | 1 |